• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

    0.6002 -0.0499 (-7.68%)
    Streaming Delayed Price Updated: 12:41 PM EDT, Apr 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Citius Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist ↗
    Best Penny Stocks to Watch in Summer 2021 With Summer upon us, which penny stocks are investors buying right now? Well, there are quite a few answers to this question. The first... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
    Via Benzinga
    News headline image
    44 Biggest Movers From Yesterday ↗
    Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at $5 per share. Alfi, Inc. (NASDAQ: ALF) shares... 
    Via Benzinga
    Topics Initial Public Offering
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
    Via Benzinga
    News headline image
    Citius Pharma Plans Interim Analysis for Mino-Lok By End of June ↗
    Citius Pharmaceuticals Inc (NASDAQ: CTXR) announced that the subsequent planned interim analysis for its Phase 3 trial of Mino-Lok for catheter-related bloodstream... 
    Via Benzinga
    News headline image
    EXCLUSIVE: Citius Pharmaceuticals CEO Myron Holubiak Talks Company Advantages ↗
    Myron Holubiak, president and CEO of Citius Pharmaceuticals Inc (NASDAQ: CTXR), appeared Thursday at Benzinga's Global Small Cap Conference for an... 
    Via Benzinga
    Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
    Via FinancialNewsMedia
    Topics Death
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Gainers Aldeyra Therapeutics (NASDAQ:ALDX) stock moved upwards by 25.29% to $13.92 during Tuesday's pre-market session. The company's market cap stands at $661.8... 
    Via Benzinga
    News headline image
    Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19 ↗
    The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of... 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Gainers Assertio Holdings (NASDAQ:ASRT) stock increased by 19.41% to $0.62 during Thursday's pre-market session. The company's market cap stands at $107.3 million... 
    Via Benzinga
    News headline image
    Exclusive: Citius Pharmaceuticals Exec Chairman On Product Pipeline, Potential $1B TAM ↗
    Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Executive Chairman Leonard Mazur told Benzinga CEO Jason Raznick Thursday that he's invested $26.5 million of his own money in the... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.